COVID 19 Clinical Trial
Official title:
Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel
Hydroxychloroquine has been approved by FDA as one of the treatment options for COVID 19.Healthcare personnel are amongst those at highest risk to contract the disease. Several health authorities are now recommending the use of hydroxychloroquine as pre-exposure prophylaxis is in health care personnel. Several studies are on going in this context. However there is a controversy regarding the dosage regimen. This drug has a half life of 22.4 days. In this study we will be comparing three different doses of Hydroxychloroquine and additionally have a control group in order to determine the efficacy of hydroxychloroquine as pre- exposure prophylaxis in healthcare personnel in various doses.
Study design:
Phase 2 proof of concept study Study Type: Interventional (Clinical Trial) Estimated
Enrollment : at least 200 participants Since the investigators have no current data on
pre-exposure prophylaxis to calculate sample size statistically, so a minimum of 50
participants in each arm will be recruited including 20% attrition rate. The investigators
will be recruiting a minimum of 200 participants in the study , that is at least 50 in each
of the four arms.
Allocation: Randomized Intervention Model: Parallel Assignment Study model: Parallel group
interventional study Location: SZABMU/PIMS Study duration: a minimum of 12 weeks from
recruitment
Materials and Methods:
Participants will be recruited after approval from Ethical Review Board .A written informed
consent will be taken from all participants. Participants fulfilling the eligibility criteria
will be randomized to 4 arms.
Arm Intervention /treatment
Experimental group 1: Hydroxychloroquine 400 mg twice a day 1,followed by 400 mg weekly for a
total of 12 weeks Drug: Hydroxychloroquin HCQ 200 mg, oral
Experimental group 2:Hydroxychloroquine 400 mg on day 1 followed by 400mg once every 3 weeks
for a total of 12 weeks Drug: Hydroxychloroquin HCQ 200 mg, oral
Experimental group 3:Hydroxychloroquine 200 mg on day 1 followed by 200 mg once every 3 weeks
for a total of 12 weeks Drug: Hydroxychloroquin HCQ 200 mg, oral
Control Group : Placebo 200mg will be given on day 1 followed by Placebo 200mg every three
weeks for a total of 12 weeks.
Base line characteristics of all participants will be recorded including age ,gender,role of
healthcare personnel, comorbidities, and drugs the participant is using.
Samples will be collected for complete picture blood, liver and renal function tests and
electrocardiogram. These tests will also be conducted every month till the end of the trial
and the participants will be monitored for any adverse effects.
During the study duration all participants will self- report any symptoms related to COVID 19
and any adverse reactions from the drug. Participants having COVID 19 symptoms at any time
will be tested by the gold standard test PCR for SARS-COV-2 using nasopharyngeal and
oropharyngeal swabs.
All participants at the end of the study will have PCR for SARS-COV-2 and if available IgM
and IgG serology to find out if they had any infection, did not get infected at all or only
had asymptomatic or mild infection.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 | |
| Completed |
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 | |
| Terminated |
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 | |
| Completed |
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 | |
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
||
| Withdrawn |
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A | |
| Recruiting |
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
||
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
| Completed |
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A | |
| Active, not recruiting |
NCT04374487 -
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
|
Phase 2 | |
| Completed |
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
||
| Completed |
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
||
| Recruiting |
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
||
| Completed |
NCT04426305 -
Community Health Workers Against COVID19
|
N/A | |
| Withdrawn |
NCT04519411 -
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
|
N/A | |
| Recruiting |
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 | |
| Completed |
NCT04403828 -
Impact of COVID-19 on Personal Protection Among Dentist in Egypt
|